Ribociclib succinate Inhibitor

Name: Ribociclib succinate Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5755087
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755087

Ribociclib succinate is a highly specific CDK4/6 inhibitor (IC50: 10nM and 39nM, respectively). It also is over 1,000-fold less potent against the cyclin B/CDK1 complex. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Ribociclib succinate, Inhibitor

Full Product Name

Ribociclib succinate

Product Synonym Names

LEE011 succinate

Form/Format

Solid. Powder

Purity/Purification

99.57%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

552.63

Solubility

DMSO: 41mg/mL (74.19mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C27H36N8O5

SMILES

OC(=O)CCC(O)=O.CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1

CAS Number

1374639-75-4

Target & IC50

CDK4: ic50 10nM
CDK6: ic50 39nM

In Vitro

Tumor growth is obviously delayed throughout the 21 days of treatment,in mice harboring the BE2C or 1643 xenografts (both, p<0.0001), although growth resumed post-treatment, CB17 immunodeficient mice bearing BE2C, NB-1643 (MYCN amplified, sensitive in vitro), or EBC1 (non-amplified, resistant in vitro) xenografts are treated once daily for 21 days with Ribociclib (LEE011; 200mg/kg) or with vehicle control. This dosing strategy is well tolerated, as no weight loss or other signs of toxicity are observed in any of the xenograft models [2].

Product Categories/Family for Ribociclib succinate, inhibitor

Cell Cycle/Checkpoint; CDK

Product References and Citations for Ribociclib succinate, inhibitor

VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer treatment, Clin Cancer Res. 2015 Jul 1;21(13):2905-10.
VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer treatment, Clin Cancer Res. 2015 Jul 1;21(13):2905-10.
Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.

Other Notes

Small volumes of Ribociclib succinate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Ribociclib succinate purchase

MBS5755087 is an inhibitor targeting Ribociclib succinate.